Gap] [Audio
contributed constant a catheter-based third year as currency ahead in expectations. on period, slightly XX% structural our increased billion to our of more ago benefited therapies. both heart the the basis $X.X from of significantly versus growth TMTT globally and patients quarter TAVR
research the important introduction of During around the the product our address to structural clinical made team needs new unmet heart advancements and in quarter, patients our world.
along at other clinical At week, and commitment large, physicians the more the pivotal science will the TCT, generating clinical presentation many IID, you take important the the Next evidence ecosystem TAVR, than more EARLY will field. CLASP Edwards data we discussing care is hear care updates. to conference, be help XX in about need. growing and of II health patients important rapidly to in with of leading diverse and this TRISCEND of advancement our
long-term remains positioning priority TAVR Our growth. for
including we next-gen more physician and patient are to technologies, patients introducing In several support global and differentiated enhancing activation awareness, through addition reaching training initiatives, leading and programs. access,
EVOQUE quarters. should the drive continue For with in of fast-growing broadening PASCAL, TMTT, Europe the of the advancing trajectory pleased growth. scale we next launching to initiatives SAPIEN over business, and pipeline are include and unique of and several MX the last launch we year. Europe, strong introduction U.S. in Edwards' innovation in our multiyear Key its
Edwards. initiatives new surgical align and we aortic growth AR, or as are our bringing by to ensuring are IHFM. differentiated the sustainable These entering generation, expanding of vision to at evidence we We heart driving therapeutic failure remain advancements. also committed management, such into Moreover, with areas, long-term innovation patients of more supported strong for or surgical implantable forefront therapies, regurgitation,
heart, to the our sharpen of Critical including took sale world structural our acquisition Care September, quarter integrating busy strategy. It We recent was actions rightsizing growth. team profitable on the in especially long-term company for the as around closed important on delivered our and focus an
As we will where growth heart be therapies detail leading across at the discussed opportunities we investor the AR, in our ahead, for for structural commitment portfolio TAVR upcoming and of differentiated our TMTT, will we creation significant conference strategies This in differentiated surgical see years outline ahead. IHFM. look value AS, TAVR
remained Now days. will when of of regional and third experienced In results pressure. although competitive a Edwards' provide I increased global few stable currency strong on QX X% group. detail by we and billing for sales billion position quarter adjusted TAVR, product pricing instances globally, $X
clinicians We are patients, continue confident evidence, to systems. and our in differentiated demonstrate care we technology, and to value health the high-quality
stroke, for We for remain focused outcomes the reported SAPIEN women those women endpoints to surgical at advancing trial, compared X-year rehospitalization held year. Ultra X presented superior in were Investigators the for receiving receiving outcome London. receiving the SAPIEN valve X a Edwards' meeting RHEIA for death, committed as valve or data ESC replacement to for at primary trial August, X on the of TAVR, exclusively evidence deeply AS aortic In patients. first-of-its-kind
The women disease. replacement, are of lifetime of aortic importance to ensuring procedures, management those with preserve especially of small their undergoing the this high-quality TAVR clinical valve of valve points success We option valve-in-valve the outstanding proud future annuli research. for their to selection for
the from the to trial date trial is controlled the community first integration the TAVR. EARLY asymptomatic largest will AS TCT, -- results at on randomized week TAVR early impact Next and with patients of trial. and studying The clinical hear severe
to U.S. Turning the
needs hospitals hospitals exploring ability future manage In to from was over sales and hospitals support constraints are team competitive quarter the in largely year-over-year our to growth additional capacity global with unchanged. Our investments rate TAVR line continue acknowledge procedure address growth scale experience rate. is although heart that growth to physicians it time. TAVR patients. to nationally, know workflow constant U.S., currency have U.S. these was believe the the We demonstrated encouraging many third historically position transcatheter to that We
Ultra was our global quarter, SAPIEN the currency sales the RESILIA. of TAVR continued U.S., growth X line Europe, the with In growth. supported sequentially, improved third market Outside position in launch TAVR our in our constant of by
outcome with delivered We expect with to centers pleased continue patient momentum as the platform. And more platform. TAVR this are best-in-class we adopt our this exceptional
Additionally, patients. congenital procedures in younger these CE will over Alterra should for Mark received require a for lifetimes. we that of system improvement heart in result Alterra number approval and quality-of-life our reduction the patients their
positive. novel the Europe, have of from its initial and in We initiated been has clinicians introduction feedback therapy
results. market to this In growth Japan, population early pressured significant among substantial to slower Japan. the address remain expanding We AS therapy undertreatment in of dedicated our
slightly expectation. TAVR are were above our results, we closing, In pleased our with QX which
growth to the year for full unchanged. remains X% guidance X% Our
However, we year-over-year some that to rate to expect later. sales onetime the items describe QX growth due be will Scott lower
is new investment Edwards and by differentiated activation indication, healthy growth, TAVR We our positioned for through our initiatives. remain high-quality sustainable our and deep technology, clinical care driven patient confident TAVR in advancing evidence, commitment that to patient
Last patients is acquisition of world, in quarter, of a in more the AR. innovators the alone the opportunity new JenaValve, of acquisitions impacts AR we announced a disease an the therapeutic the provide in and patients area treatment today. XXX,XXX JC and These unmet needs Medical than that untreated largely around deadly U.S. address early to
and believe best develop, in to technologies. As Edwards the positioned innovation, we study valve is novel deliver pioneer
Medical. I in AR JC J-Valve trial with implant performed the system the JOURNEY am Edwards pivotal pleased to first acquired report that our from recently we
announcement As acquisition customary transaction, noted to closing the in our review conditions. regulatory of and subject JenaValve is other
We request acquisition closing anticipate are mid-XXXX. responding second their the connection a to with FTC in the from review and
turning TMTT. Now to
a the EVOQUE system, repair PASCAL options patients the need. MX including set in many broad SAPIEN and to upcoming the tricuspid the system, innovations, provide unique replacement serve Our diverse system treatment and of replacement complex mitral
XX% over led the in by the prior sales, QX $XX growth representing pleased are PASCAL growth were year. achieving We with globally. million results, Sales
of the continued the in initial We Europe. commercial expansion U.S. and EVOQUE
forward and diagnosed we differentiated in trial adoption, see and continue expanding patients strong CLASP ongoing even a next studying We existing presenting PASCAL procedures therapy long and TCT of the tricuspid as therapy to growth. DMR mitral both the resulting X-year Globally, at Adoption sites new growth technology world. around treated of in pivotal as more IID double-digit is experiencing outcomes look week. stronger patients to
earlier-than-expected alone. CLASP TR against tricuspid PASCAL studying pleased of II regurgitation medical trial differentiated TR with given to We the the This randomized achievement the suffering completion PASCAL. therapy of from great for is also are enrollment optimal for patients patients characteristic announce news
as and trial The the successfully EVOQUE progress activated centers. our to initial we new launch continues both well Europe in sites beyond U.S.
high-touch teams clinical patient their into to our as field on new increasing in bring they We to deliver model outcome. to excellent achieve sites order our are support practice EVOQUE also
year X XXX-patient next full the strong will unmet the at in TRISCEND presented II therapy to be The interest study The week. highlight pivotal at large this cohort of also TCT continues need.
for effect to the in years access patients, in U.S. The October XX-millimeter, for a above support valve, this patients size efforts for eligible X will the need. fourth became more add-on is therapy technology population. Medicare's larger-size with addition this patient larger addressable was EVOQUE reimbursement continued our payment valve expand additional In the standard of On new many EVOQUE increased and to X, in recently will reach payment and breakthrough approved the U.S.
$XXX high the adoption million ongoing year global end full million. on PASCAL our the TMTT therapies, we sales at X in $XXX Based confident EVOQUE, and our to remain of guidance of
of $XXX was X% MITRIS In Edwards million surgical third Growth sales year. INSPIRIS, by technologies surgical, KONECT. operation over premium increased global driven from continuing prior strong adoption of quarter the and
surgically, is we We the schedule. in continue continue procedure of RESILIA MITRIS expand see the We body momentous for ahead undergoing our to patients those for globally studying growth enrollment to and evidence procedures. best complex of treated expand trial clinical Europe -- many overall positive including
COMMENCE In with Surgery, addition, treated Journal shows tissue AR Thoracic the Cardiovascular which valves outcome has for been years. patients published our in and after AR RESILIA X with of positive manuscript
INSPIRIS Europe, IMPACT, and a INDURE implanted X shown registries with have favorable younger investigator-initiated more in out RESILIA patients and Finally, complex were the who outcome valve. of
believe sales full to year XXXX summary, we will continue In that our growth X% be surgical to X%.
QX, Turning to structural making heart our we or of acquisition implantable marking the IHFM. Endotronix, management, closed heart entry failure. into failure -- In
is structural patients in ensures vision need, to in for of a that best-in-class growth. IHFM for other consistent Our outcome with platform heart establish our multiyears resulting technologies,
HFSA the XX-month early an system, to heart implantable at patients pivotal artery Conference, released intervention. the managed HF the sensor which targeted results a strong trial Cordella pressure with benefit We pulmonary failure significant demonstrated proactive allowing from
also In the has trial value initiated, for and the implantable demonstrate heart management. of management HF further proactive the failure which addition, data-driven will heart extend II been base failure evidence
will completion our commercial ramp building over to recent on commercialization, we and physician focus Revenue ensure system U.S. in disciplined the case quality of is the of outcome, patient approval as team, and With our on support time the Cordella of cases, deploying usage focus our high first outcomes. training, engagement.
now turn over I the will And call Scott. to
